14.01.2022 - DURHAM, N.C., Jan. 14, 2022 (GLOBE NEWSWIRE) - Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s completed Phase 2 and Phase 3 clinical studies of berdazimer 10.3% gel (previously referred to as . Seite 1
Novan Reports Positive Topline Results from Pivotal Phase 3 Trial of SB206 in Patients with Molluscum Contagiosum - B-SIMPLE4 achieves statistical significance. | June 11, 2021